Skip to main content

Table 3 Decrease in monthly seizure frequency

From: Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy

    

95% Confidence Interval

 

% of animals with

Variable

Cohort

N

%Decrease

LCL

UCL

p-value

any reduction

>50% reduction

MSF

A

16

15.46

−67.03

57.22

0.607

50.0

37.5

A*

15*

27.24

−38.96

61.90

0.310

53.3

40.0

B

11

35.73

1.69

57.94

0.043

81.8

36.4

C

7

39.41

−3.77

64.58

0.063

71.4

42.9

A + B

27

26.29

−7.36

49.44

0.180

63.0

37.0

A + B + C

34

27.75

−1.51

48.57

0.060

64.7

38.2

MCD

A

16

−16.77

−161.95

47.95

0.688

  

A*

15*

4.69

−98.58

54.25

0.890

  

B

11

17.88

−46.52

53.98

0.466

  

C

7

8.06

−105.03

58.77

0.806

  

A + B

27

−1.21

−68.03

−64.05

0.962

  

A + B + C

34

0.80

−50.53

34.69

0.969

  
  1. MSF = (Number of Seizures/Number of days) x 28 days. MCD = (Number of Cluster days/Number of days) x 28 days. Significant %Decrease (p < 0.05) is bolded. In addition, the paired t-test was applied to the corresponding log-transformed data values separately for each cohort and the two combinations of cohorts (i.e., cohort A + B and all 3 cohorts combined). The displayed p-value is derived from this paired t-test. The fraction of animals showing any reduction and >50% reduction of MSF (“Responder rate”) is given
  2. *excluding animal No. 6 of cohort A as outlier
Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us